ATGAM®▼ (horse anti-human T-lymphocyte immunoglobulin) dosing and administration

There are three different approved dosing regimens to administer ATGAM®

The currently approved posology is a total dose of 160 mg/kg bw administered as part of standard IST over 4–10 days as either:

Dose adjustments¹  

• Dose adjustment of ATGAM® is not required in elderly patients above 65 years of age.
• Specific clinical studies have not been performed to assess the effect of renal or hepatic impairment on the pharmacokinetics of ATGAM®

• ATGAM® must only be administered by experienced physicians in well-equipped facilities
• ATGAM® is supplied in 5 mL ampoules and administered intravenously, preferably via a high-flow central vein through an in-line filter¹
• Prior to administrating ATGAM®, the following are also recommended:
  • Pre-medication with corticosteroids and antihistamines 
  • Fever-reducing agents to increase patient tolerability 
  • Skin testing to identify patients at risk of life-threatening allergic reaction

Steps of ATGAM® IV infusion¹

• While patients are receiving ATGAM® via infusion and after the infusion, the patient should be kept under continuous observation during and after the infusion for possible allergic reactions, including respiratory distress and Cytokine Release Syndrome¹
• Thrombocytopenia and neutropenia can be associated with the administration of ATGAM®¹
• A second course of ATGAM® may be initiated after failure to respond to, or relapse of, a first course of treatment. A systemic reaction to ATGAM such as a generalized rash, tachycardia, dyspnoea, hypotension, or anaphylaxis precludes any additional administration of Atgam.²